Literature DB >> 35261448

Strongyloides stercoralis and cytomegalovirus coinfection in a patient with a transplanted kidney.

Mohammad Amin Fallahzadeh1, Nina T Rico1,2, Elham Vahhab3, Huang He3, Dina Abdelwahab Elhamahmi1,2, Uriel Sandkovsky1,4.   

Abstract

Cytomegalovirus is a major opportunistic infection after transplantation with significant morbidity and mortality for solid organ transplant recipients. Unrecognized infection with Strongyloides stercoralis may result in significant morbidity and mortality in immunocompromised patients. Coinfection with multiple pathogens is possible, leading to diagnostic delays, and may make treatment more challenging. We report a case of coinfection with S. stercoralis and cytomegalovirus in a kidney transplant patient that resulted in pneumonitis, gastritis, and cholecystitis.
Copyright © 2021 Baylor University Medical Center.

Entities:  

Keywords:  Cholecystitis; gastritis; hyperinfection; immunosuppression; ivermectin; pneumonitis

Year:  2021        PMID: 35261448      PMCID: PMC8865324          DOI: 10.1080/08998280.2021.1997262

Source DB:  PubMed          Journal:  Proc (Bayl Univ Med Cent)        ISSN: 0899-8280


  20 in total

1.  Endoscopic and histopathologic findings of Strongyloides stercoralis infection in a patient with AIDS.

Authors:  Kerith Overstreet; Jaime Chen; Jessica Wang Rodriguez; Gregory Wiener
Journal:  Gastrointest Endosc       Date:  2003-12       Impact factor: 9.427

2.  Multiple-dose versus single-dose ivermectin for Strongyloides stercoralis infection (Strong Treat 1 to 4): a multicentre, open-label, phase 3, randomised controlled superiority trial.

Authors:  Dora Buonfrate; Joaquin Salas-Coronas; José Muñoz; Begoña Trevino Maruri; Paola Rodari; Francesco Castelli; Lorenzo Zammarchi; Leila Bianchi; Federico Gobbi; Teresa Cabezas-Fernández; Ana Requena-Mendez; Gauri Godbole; Ronaldo Silva; Marilena Romero; Peter L Chiodini; Zeno Bisoffi
Journal:  Lancet Infect Dis       Date:  2019-09-23       Impact factor: 25.071

3.  Strongyloidiasis-related deaths in the United States, 1991-2006.

Authors:  Curtis Croker; Roshan Reporter; Matt Redelings; Laurene Mascola
Journal:  Am J Trop Med Hyg       Date:  2010-08       Impact factor: 2.345

Review 4.  Diagnosis of Strongyloides stercoralis infection.

Authors:  A A Siddiqui; S L Berk
Journal:  Clin Infect Dis       Date:  2001-09-05       Impact factor: 9.079

Review 5.  Novel approaches to the diagnosis of Strongyloides stercoralis infection.

Authors:  D Buonfrate; F Formenti; F Perandin; Z Bisoffi
Journal:  Clin Microbiol Infect       Date:  2015-04-14       Impact factor: 8.067

6.  Use of enzyme-linked immunosorbent assay and dipstick assay for detection of Strongyloides stercoralis infection in humans.

Authors:  H Rogier van Doorn; Rob Koelewijn; Henk Hofwegen; Henk Gilis; Jose C F M Wetsteyn; Pieter J Wismans; Claudine Sarfati; Tony Vervoort; Tom van Gool
Journal:  J Clin Microbiol       Date:  2006-12-06       Impact factor: 5.948

Review 7.  Strongyloides stercoralis in the Immunocompromised Population.

Authors:  Paul B Keiser; Thomas B Nutman
Journal:  Clin Microbiol Rev       Date:  2004-01       Impact factor: 26.132

8.  Comparative Diagnosis of Strongyloidiasis in Immunocompromised Patients.

Authors:  Viravarn Luvira; Kitti Trakulhun; Mathirut Mungthin; Tawee Naaglor; Nirattar Chantawat; Wallop Pakdee; Danabhand Phiboonbanakit; Paron Dekumyoy
Journal:  Am J Trop Med Hyg       Date:  2016-06-13       Impact factor: 2.345

9.  Biliary Strongyloides stercoralis With Cholecystitis and Extensive Portal Vein Thrombosis.

Authors:  Laura M Filkins; David C Gaston; Blaine Mathison; Timothy Smith; Marc Roger Couturier; Ryan D Murphy; Claire Ciarkowski; Kimberly E Hanson; Paloma F Cariello
Journal:  Open Forum Infect Dis       Date:  2017-10-08       Impact factor: 3.835

10.  Fatal outcome in a patient under immunosuppressant therapy infected with human T-lymphotropic virus type 1 (HTLV-1), cytomegalovirus (CMV) and Strongyloides stercoralis: a case report.

Authors:  Chisato Ashida; Koji Kinoshita; Yuji Nozaki; Masanori Funauchi
Journal:  BMC Infect Dis       Date:  2020-07-02       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.